-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Lenvatinib is currently approved for the first-line treatment of patients with advanced liver cancer
.
We also know that PD-1 inhibitors are also used in patients with advanced liver cancer
We included 56 patients with unresectable liver cancer who were treated with Lenvatinib from December 2018 to March 2021 in the Oncology Comprehensive Center of Nanjing University Drum Tower Hospital
.
There are 48 patients who can be analyzed and well documented, including 39 patients with hepatocellular carcinoma (HCC) and 9 patients with intrahepatic cholangiocarcinoma (ICC)
During the follow-up period, 20 (43.
75%) patients died
.
The mOS of the overall population is 22.
Overall population OS and PFS
The mOS and mPFS of HCC patients who received lenvatinib monotherapy were 22.
43 months (95% CI not reached) and 11.
60 months (95% CI 7.
46-15.
74), respectively
.
HCC monotherapy for OS and PFS
The mOS and mPFS of the lenvatinib combined with PD-1 inhibitor treatment group of HCC patients were 21.
77 months (95% CI, 3.
68-39.
86) and 7.
10 months (95% CI, 2.
8-11.
4), respectively
.
HCC combined treatment of OS and PFS
However, the mOS of the lenvatinib combined with PD-1 inhibitor treatment group of ICC patients has not yet reached; and the mPFS is 8.
63 months (95% CI, 0-17.
67)
.
ICC monotherapy for OS and PFS
Twenty-one patients (43.
8%) and 12 patients (25%) had elevated transaminase levels (grades 1-2 and 3-4, respectively)
.
There were 10 cases (20.
A HCC patient receiving combination therapy achieved complete remission during the first review
.
In addition, 14 patients achieved partial remission (including 2 HCC patients receiving lenvatinib monotherapy, 4 and 8 ICC and HCC patients receiving combination therapy)
Efficacy evaluation
Among 39 HCC patients, 6 had negative baseline AFP data
.
We divided the remaining 33 patients into low (≤200 ng/mL) (n=18) and high (>200 ng/mL) (n=15) AFP level groups
Prognostic analysis of AFP stratification in HCC patients
In addition, we found that in 9 patients with ICC, the OS between patients with high CA-199 (>150 ng/mL) (n=4) and patients with low CA-199 (≤150 ng/mL) (n=5) There is no significant difference (P=0.
1401)
.
But there are significant differences in PFS statistical significance (P = 0.
statistics
The prognostic analysis of CA199 stratified ICC patients
In summary, studies have shown that Lenvatinib is effective in treating Chinese patients with advanced liver cancer and its toxicity is controllable
Original source:
Zhu S, Liu C, Dong Y, Shao J, Liu B and Shen J (2021) A Retrospective Study of Lenvatinib Monotherapy or Combined With Programmed Cell Death Protein 1 Antibody in the Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma in China.
Leave a message here
